Testing two drugs for Crohn's with weight issues
Treatments studied
Part of Digestive system, Hormones & metabolism clinical trials.
This trial tests two study drugs, mirikizumab and tirzepatide, in people with moderate to severe Crohn's disease who also have overweight or obesity. The goal is to see if these treatments can help control Crohn's symptoms and inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Crohn's disease or Crohn's with fistulas around the anus.
- Your body mass index (BMI) is 30 or higher, or at least 27 with a weight-related condition like high blood pressure, type 2 diabetes, high cholesterol, sleep apnea, or heart disease.
- Your Crohn's is moderately to severely active, meaning you have symptoms like abdominal pain or diarrhea and inflammation seen on a colonoscopy.
- You have already tried at least one standard Crohn's treatment that didn't work well enough or caused side effects.
- You do not have a current infection, abscess, stoma, or a history of more than 3 small bowel surgeries.
- You have not had significant weight change (more than 5% of your body weight) in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding mirikizumab to the weight-loss drug tirzepatide helps people with moderate-to-severe ulcerative colitis who also have obesity or overweight. It aims to see if the combination reduces bowel inflammation and helps with weight management.
This study tests a new targeted therapy for adults with moderate to severe Crohn's disease who haven't responded well to other treatments. It aims to reduce inflammation and improve symptoms.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This trial tests an experimental drug for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The drug aims to reduce inflammation and may help improve symptoms.
This study tests mirikizumab to reduce inflammation and symptoms in children with Crohn’s disease that is currently active. It may help if your Crohn’s has not improved enough (or stopped working) with at least one other Crohn’s medicine.
This trial tests a medication called Mirikizumab for adults over 60 with moderate to severe Crohn's disease or ulcerative colitis. It aims to see if the drug is safe and effective for older adults with these conditions.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.